ARVN - Arvinas Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

853.4M

Cash

1.169B

Avg Qtr Burn

-88.53M

Short % of Float

18.69%

Insider Ownership

7.16%

Institutional Own.

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Vepdegestrant (ARV-471) (oral ER-targeting PROTAC® protein degrader) + palbociclib Details Breast cancer, Cancer, Solid tumor/s	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471)(oral ER-targeting PROTAC® protein degrader) Details Breast cancer, Cancer, Solid tumor/s Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARV-766 +/- abiraterone Details Solid tumor/s, Castration-resistant prostate cancer, Prostate cancer, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bavdegalutamide (ARV-110) (PROTAC protein degrader) +/- abiraterone Details Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471)+CDK4 inhibitor Details Cancer, Solid tumor/s, Breast cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471)+CDK7 inhibitor (samuraciclib) Details Cancer, Solid tumor/s	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARV-102 (PROTAC® protein degrader) Details Neurodegenerative disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARV-393 [PROTAC BCL6 degrader] Details Cancer, B-cell lymphoma, Blood cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.